[go: up one dir, main page]

PE20081482A1 - Capsulas de gelatina que contienen un acido - Google Patents

Capsulas de gelatina que contienen un acido

Info

Publication number
PE20081482A1
PE20081482A1 PE2007001792A PE2007001792A PE20081482A1 PE 20081482 A1 PE20081482 A1 PE 20081482A1 PE 2007001792 A PE2007001792 A PE 2007001792A PE 2007001792 A PE2007001792 A PE 2007001792A PE 20081482 A1 PE20081482 A1 PE 20081482A1
Authority
PE
Peru
Prior art keywords
acid
composition
refers
filling material
gelatin capsule
Prior art date
Application number
PE2007001792A
Other languages
English (en)
Inventor
Isabel Ottinger
Agnes Taillardat
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37890457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081482(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20081482A1 publication Critical patent/PE20081482A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA EN FORMA DE CAPSULA DE GELATINA LA CUAL COMPRENDE: a) UNA CUBIERTA DE CAPSULA DE GELATINA BLANDA Y b) UN MATERIAL, SEMILIQUIDO O LIQUIDO COMO MICROEMULSION, DE RELLENO; EL CUAL CONTIENE ENTRE 0.01% AL 20% DE UN ACIDO, SELECCIONADO DE ACIDO FUMARICO, ACIDO FOSFORICO, ACIDO MALICO, ACIDO ASCORBICO, ENTRE OTROS, EN EL QUE DICHO ACIDO MIGRA DESDE EL MATERIAL DE RELLENO HACIA LA CUBIERTA DE CAPSULA E INHIBE LA FORMACION DE PELICULA; EL AGENTE ACTIVO PUEDE ESTAR PRESENTE EN HASTA UN 20% DEL PESO TOTAL DE LA COMPOSICION. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION. DICHA COMPOSICION CONTIENE PREFERENTEMENTE 7-TERBUTOXI-IMINO-METIL-CAMPTOTECINA QUE ES UN INHIBIDOR DE TOPOISOMERASA I, UTIL EN EL TRATAMIENTO DE CANCER
PE2007001792A 2006-12-20 2007-12-14 Capsulas de gelatina que contienen un acido PE20081482A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06126698 2006-12-20

Publications (1)

Publication Number Publication Date
PE20081482A1 true PE20081482A1 (es) 2008-12-23

Family

ID=37890457

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001792A PE20081482A1 (es) 2006-12-20 2007-12-14 Capsulas de gelatina que contienen un acido

Country Status (15)

Country Link
US (1) US20100068265A1 (es)
EP (1) EP2120889A1 (es)
JP (1) JP2010513351A (es)
KR (1) KR20090094373A (es)
CN (1) CN101563072A (es)
AR (1) AR064419A1 (es)
AU (1) AU2007334856A1 (es)
BR (1) BRPI0720489A2 (es)
CA (1) CA2672400A1 (es)
CL (1) CL2007003698A1 (es)
MX (1) MX2009006735A (es)
PE (1) PE20081482A1 (es)
TW (1) TW200833375A (es)
UY (1) UY30810A1 (es)
WO (1) WO2008074479A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012002464A1 (ja) * 2010-06-30 2012-01-05 持田製薬株式会社 ω３脂肪酸の配合製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60239418A (ja) * 1984-05-15 1985-11-28 Nippon Kayaku Co Ltd エトポシド軟カプセル製剤
DE4001622A1 (de) * 1990-01-20 1991-07-25 Thomae Gmbh Dr K Orale arzneimittelformen von pimobendan
US5620704A (en) * 1994-11-07 1997-04-15 Warner-Lambert Company Process for stabilizing gelatin products
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
WO1997033568A1 (en) * 1996-03-12 1997-09-18 Novartis Ag Filled gelatin capsules having a reduced degree of cross-linking
US6228894B1 (en) * 1998-04-17 2001-05-08 Enhanced Derm Technologies, Inc. Softgel-compatible composition containing retinol
ES2302926T5 (es) * 2002-04-25 2012-08-23 Banner Pharmacaps, Inc. Cápsula blanda masticable
EP1549299B1 (en) * 2002-06-05 2014-08-20 IVAX Pharmaceuticals s.r.o. Reduction of gelatin cross-linking

Also Published As

Publication number Publication date
UY30810A1 (es) 2008-07-31
AR064419A1 (es) 2009-04-01
KR20090094373A (ko) 2009-09-04
CN101563072A (zh) 2009-10-21
WO2008074479A1 (en) 2008-06-26
JP2010513351A (ja) 2010-04-30
EP2120889A1 (en) 2009-11-25
CA2672400A1 (en) 2008-06-26
US20100068265A1 (en) 2010-03-18
AU2007334856A1 (en) 2008-06-26
BRPI0720489A2 (pt) 2014-02-04
CL2007003698A1 (es) 2008-07-18
MX2009006735A (es) 2009-06-30
TW200833375A (en) 2008-08-16

Similar Documents

Publication Publication Date Title
CO6290641A2 (es) Preparacion de capsula que contiene los ingredientes farmaceuticamente activos liquidos y solidos, la cual presenta exelentes propiedades de los ingredientes farmaceuticamente activos
PE20080765A1 (es) Formas de dosificacion farmaceutica
CO6731103A2 (es) Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas
PE20061136A1 (es) Sistema de capsulas blandas que no son de gelatina
PE20071310A1 (es) Formulaciones liquidas de fenilefrina
PE20080374A1 (es) Composiciones farmaceuticas de ropinirol
ECSP15039103A (es) Formulación de liberación sostenida de mosapride que proporciona efectos farmacológicos y clínicos con administración una vez al día
MX2013004699A (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.
PE20131063A1 (es) Composicion acuosa que contiene bromhexina
CL2004000899A1 (es) Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion.
CO6300932A2 (es) Composicion solida termoestable que comprende sustancias mejoradas de permeabilidad para ingredientes farmaceuticos activos de permeabilidad deficiente
PE20060002A1 (es) Combinaciones antineoplasicas de cci-779 y rituximab
PE20141539A1 (es) Una nueva composicion terapeutica que contiene apomorfina como principio activo
CO6220902A2 (es) Formulacion en polvo del valganciclovir
ES2720954T3 (es) Formulaciones estabilizadas de estatina
CL2013002700A1 (es) Cápsula suave ingerible que contiene inositol y excipientes, o inositol, excipientes y al menos un principio activo adicional, tal como ácido fólico, polifenoles de cocoa, genisteína, l-arginina, vitamina e, selenio, n-acetilcisteína y melatonina; útil para el tratamiento del ovario poliquístico, resistencia a la insulina y otros
AR088918A1 (es) Composiciones antitranspirantes anhidras
CO6341514A2 (es) Método para reducir la variabilidad de la absorción de paracetamol en pacientes con dismotilidad gástrica
SI3060203T1 (en) A effervescent tablet containing a high level of aspirin
PE20081482A1 (es) Capsulas de gelatina que contienen un acido
PE20081443A1 (es) Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.
MX2016000605A (es) Composiciones y dispositivos para atomizador antitranspirante.
CL2007002363A1 (es) Procedo para retrasar o prevenir la cristalizacion de un material que comprende crear gotitas encapsuladas de una solucion de un material activo que es sustancialmente insoluble en condiciones acuosas, donde el agente encapsulante es una pelicula for
PE20060639A1 (es) Composicion farmaceutica en forma de comprimido de residencia gastrica que contiene un principio activo

Legal Events

Date Code Title Description
FD Application declared void or lapsed